Stay updated with breaking news from Athogen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer's disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.
In a recent article published in the journal Immunity, researchers explained the concept of immunological imprinting and its underlying principles. They also discussed its potential role in the context of coronavirus disease 2019 (COVID-19) vaccines.
The paper presents a systematic analysis of the global burden of bacterial antimicrobial resistance in 2019. The authors highlight the urgent need for action to address this growing public health threat.
A new bioengineered drug candidate demonstrated superior performance to a standard antibiotic at treating mice infected with Staphylococcus aureus, according to results from early testing published April 24 in Cell Host & Microbe.
Researchers at NYU Grossman School of Medicine and Janssen Biotech, Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus – a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.